
Conference Coverage
about 3 hours ago
Redefining Oncology Through the Academic-Community Dyad Modelabout 7 hours ago
Disparities Drive Shifting Pancreatic Cancer Survival TrendsLatest Content

New Frontline Strategies for Advanced Gastric Cancer: Dani Castillo, MD

Redefining Oncology Through the Academic-Community Dyad Model

What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells?

Disparities Drive Shifting Pancreatic Cancer Survival Trends

Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

This week, we look at 5 key health care changes the Trump Administration made in 2025, changes to the immunization schedule, and new research on telehealth accessibility.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

President Donald J. Trump's health care overhaul during the first year of his second term reshapes Medicaid, vaccine policies, and drug pricing.












































































